Searched for
GLENMARK SPECIALTY
These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsIn just a few days, the Q1 earnings season for FY27 will start. But before that will come the season of business updates. And that needs to...- For investors looking beyond the short-term horizon: 5 mid-cap stocks from different sectors with upside potential up to 28%All is once again quiet on the US-Iran war front, and some kind of dialogue to resolve the issues between the two seems to be still underwa...
- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Glenmark Pharmaceuticals wins USFDA nod for fluticasone inhalerGlenmark Pharmaceuticals has secured a significant approval from the US FDA for its inhaler fluticasone propionate. This marks a key step i...
- Glenmark’s nasal spray Ryaltris gets China’s NMPA nod for allergic rhinitis; to be commercialised by Grand PharmaRyaltris is a fixed-dose combination of olopatadine, an antihistamine and mometasone furoate, a corticosteroid to treat the symptoms of all...
- Glenmark gets USFDA nod to market generic drugGlenmark Pharmaceuticals announced that it has received USFDA approval to market its generic Esomeprazole Magnesium delayed-release capsule...
- Glenmark gets USFDA nod to begin trials for potential cancer drugThe USFDA approval paves the way for Glenmark's subsidiary Glenmark Specialty to proceed with a Phase 1/2, first-in-human, clinical study o...
- Glenmark's partner Hikma launches specialty drug Ryaltris in USRyaltris is the only fixed-dose combination of olopatadine hydrochloride and mometasone furoate approved by the USFDA for the treatment of ...
- Glenmark receives DCGI nod to conduct clinical trials of its molecule on cancer patientsThe Mumbai-based drug major said, GRC 54276 has shown tumor cell killing ability in preclinical studies as a single agent and as well in co...
- Glenmark Pharma inks exclusive licensing agreement with Lotus InternationalGlenmark will receive an upfront payment as well as regulatory and sales-based milestone payments from Lotus, it added.
- Glenmark gets USFDA nod for nasal spray to treat seasonal allergic rhinitisGlenmark Pharmaceuticals on Friday said its subsidiary has received approval from the US health regulator to market Ryaltris, a nasal spray...
- Glenmark inks pact with Menarini Group to commercialise nasal spray in EuropeGlenmark Specialty, a Switzerland-based unit of the company, has entered into an exclusive licensing agreement with the Menarini Group for ...
- Glenmark gets approval from Australian regulator to commercialise RyaltrisGlenmark is entitled to receive commercial milestone payments from Seqirus.
- Neutral Glenmark Pharmaceuticals with a target of Rs 960: UBSExpect base US biz to improve as a result of recent launches in dermatology. UBS has forecast a 33% EPS CAGR over FY16-18E for Glenmark Pha...
- Glenmark working on proprietary product rolloutThe company plans to build a global manufacturing footprint, increase presence in complex generics, launching of specialty business in the ...
- Buy Cipla, Glenmark: Seshadri Bharathan, KSEMA Fincon LtdCipla, Glenmark look very attractive. These companies are exhibiting very strong growth of more than 20% year on year based on global gener...
- Glenmark to reorganise biz into specialty, genericsThe new generic entity, called Glenmark Generics, will be a subsidiary of the company and will be listed on the bourses by April-June 2008-...
Load More
